289 related articles for article (PubMed ID: 12006543)
1. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
[TBL] [Abstract][Full Text] [Related]
2. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.
Nieto-Rementería N; Pérez-Yarza G; Boyano MD; Apraiz A; Izu R; Díaz-Pérez JL; Asumendi A
Br J Dermatol; 2009 Mar; 160(3):519-26. PubMed ID: 19067706
[TBL] [Abstract][Full Text] [Related]
3. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
4. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
5. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling.
Zhang C; Li B; Zhang X; Hazarika P; Aggarwal BB; Duvic M
J Invest Dermatol; 2010 Aug; 130(8):2110-9. PubMed ID: 20393484
[TBL] [Abstract][Full Text] [Related]
6. About the cutaneous targets of bexarotene in CTCL patients.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
[TBL] [Abstract][Full Text] [Related]
7. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Richon V; Ni X; Talpur R; Duvic M
J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
[TBL] [Abstract][Full Text] [Related]
8. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
[TBL] [Abstract][Full Text] [Related]
9. Central hypothyroidism associated with retinoid X receptor-selective ligands.
Sherman SI; Gopal J; Haugen BR; Chiu AC; Whaley K; Nowlakha P; Duvic M
N Engl J Med; 1999 Apr; 340(14):1075-9. PubMed ID: 10194237
[TBL] [Abstract][Full Text] [Related]
10. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
11. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
[TBL] [Abstract][Full Text] [Related]
12. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
Zhang C; Ni X; Konopleva M; Andreeff M; Duvic M
J Invest Dermatol; 2004 Aug; 123(2):380-7. PubMed ID: 15245439
[TBL] [Abstract][Full Text] [Related]
13. RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
Wang L; DeMarco SS; Peaks MS; Maiorana-Boutilier AL; Chen J; Crouch MJ; Shewchuk BM; Shaikh SR; Phillips CM; Bridges LC
Exp Dermatol; 2017 Nov; 26(11):1004-1011. PubMed ID: 28370539
[TBL] [Abstract][Full Text] [Related]
14. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
Dummer R; Beyer M; Hymes K; Epping MT; Bernards R; Steinhoff M; Sterry W; Kerl H; Heath K; Ahern JD; Hardwick JS; Garcia-Vargas J; Baumann K; Rizvi S; Frankel SR; Whittaker SJ; Assaf C
Leuk Lymphoma; 2012 Aug; 53(8):1501-8. PubMed ID: 22239668
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.
Wu J; Wood GS
JAMA Dermatol; 2018 Oct; 154(10):1191-1198. PubMed ID: 30167641
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
17. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
18. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
19. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma.
Zhang C; Duvic M
Dermatol Ther; 2003; 16(4):322-30. PubMed ID: 14686975
[TBL] [Abstract][Full Text] [Related]
20. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
